FDA approval of mitapivat signals a shift in thalassaemia care, offering the first oral option to treat chronic anaemia.
In Focus delivers deeper coverage of the political, cultural, and ideological issues shaping America. Published daily by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback